drugset / Trial / NCT00900614
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.
Timeline
- Start
- 2009-05
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | eprenetapopt | Small molecule | — | Intravenous |